JPMorgan Chase & Co. Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price boosted by JPMorgan Chase & Co. from $28.00 to $35.00 in a report issued on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also commented on TEVA. Barclays initiated coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price objective on the stock. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, December 8th. Bank of America raised their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, September 24th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus price target of $31.13.

Teva Pharmaceutical Industries Trading Down 0.1%

TEVA opened at $30.11 on Tuesday. The firm has a market capitalization of $34.53 billion, a P/E ratio of 50.18, a P/E/G ratio of 1.79 and a beta of 0.67. The firm’s 50 day moving average is $23.83 and its 200-day moving average is $19.81. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $30.44. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Insider Transactions at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 200,000 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares in the company, valued at $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president directly owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 532,360 shares of company stock worth $14,364,929. 0.55% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Hudson Bay Capital Management LP increased its position in Teva Pharmaceutical Industries by 87.5% in the third quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock worth $4,545,000 after buying an additional 105,000 shares during the period. Steadtrust LLC grew its position in shares of Teva Pharmaceutical Industries by 58.1% during the third quarter. Steadtrust LLC now owns 37,300 shares of the company’s stock worth $753,000 after acquiring an additional 13,700 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $1,392,000. CIBC Private Wealth Group LLC increased its holdings in shares of Teva Pharmaceutical Industries by 15.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after acquiring an additional 540 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $234,000. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.